A Phase 2 Randomized, Double-Blind, Clinical Trial Of Trilaciclib Versus Placebo In Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel In The 2nd/3rd Line Setting (PRESERVE 4)